Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM

K-Number: K820192 · 1982-03-11

ApplicantHyland Therapeutic Div., Travenol Laboratories
Decision Date1982-03-11
Product CodeGRP
Advisory CommitteeMI
DecisionSubstantially Equivalent

Device Summary

HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM is the device name listed in this FDA 510(k) record. The listed applicant is Hyland Therapeutic Div., Travenol Laboratories. It received FDA 510(k) clearance on 1982-03-11 under 510(k) number K820192. The device is classified under product code GRP. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM?

HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM is a medical device that received FDA 510(k) clearance on 1982-03-11. The listed applicant is Hyland Therapeutic Div., Travenol Laboratories. The 510(k) number is K820192.

When did HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM receive FDA 510(k) clearance?

HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM received FDA 510(k) clearance on 1982-03-11, under 510(k) number K820192.

Who is the listed applicant for HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM?

The FDA 510(k) record lists Hyland Therapeutic Div., Travenol Laboratories as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM?

The FDA product code for HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM is GRP.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Hyland Therapeutic Div., Travenol Laboratories as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K820835ALUMINA SILICA-ACTIVATED PARTIAL THROMK812220NEPHELOMETRIC SOLID TURBIDITY STANDARDK810078Q-PAK THERAPEUTIC DRUG MONIT. CONTROL SK810077OMEGA THERAPEUTIC DRUG MONIT. CONTROL S.K802610ALERT A,HDL-APOLIPOROTEIN A, TEST KITK791113LOW IONIC STRENGTH SOLUTION (LISS)

View all 44 devices →

Related Devices (Code: GRP)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K884967BACTIGEN(R) H. INFLUENZAE TYPE BArmkel, LLCK854490IMMUNOSCAN DIRECT HEMOPHILUS INFLUENZAE TYPE B TESAmerican Micro ScanK831525H-FLU B ELISA TESTSeragen Diagnostics, Inc.K823348H. INFLUENZA B ANTISERA FOR CIEDiagnostica, Inc.K821266BBL DIRECTIGEN MENINGITIS TEST KITBd Becton Dickinson Vacutainer Systems Preanalytic

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑